Pharmaceutical CEOs are on notice about sky-high drug prices as President Donald Trump demands a recalibration of what ...

We will be totally self-sufficient for the supply of medicines to American patients.” AstraZeneca CEO Pascal Soriot on the ...

It plans to invest $50 billion in the US over five years, including building its largest-ever manufacturing facility in ...

New data highlights an unprecedented crisis in National Health Service patient waiting lists and sheds light on how the ...

Today’s Forbes CFO newsletter focuses on Aradhana Sarin’s journey from treating patients to becoming what she calls a ...

From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.

One of Trump's demands was that the CEOs' companies limit drug costs for states' Medicaid plans to "most-favored nation" ...

In an earnings call on July 29th, in which the company reported a 13% increase in half-year profits, he said about Britain ...

Glencore has axed plans to move its main stock market listing away from London, in a boost for the London Stock Exchange.

President Donald Trump has given major pharmaceutical companies 60 days to slash prescription drug prices or face action.

The announcement of a 15% tariff on pharmaceutical imports to the U.S. from the European Union may have not been the ideal ...

Today’s Forbes Daily newsletter covers Trump’s Fed chair candidates, Palantir’s rising share price, RFK cancels vaccine funding, GOP pushes for more on Epstein and more.